Non-arteritic Anterior Ischemic Optic Neuropathy NAION Study
If your patients experienced acute sudden vision loss in less than 14 days of the vision loss. Please contact our PI immediately. You do NOT need to confirm a diagnosis of NAION before referring the patient.
A Phase 2/3, randomized, double-masked, sham- controlled trial of QPI-1007 delivered by single or multi-dose intravitreal injection(s) to subjects with recent onset of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION).
The study drug is designed to temporarily block cells from making caspase-2, a protein that activates cell death.
- Positive diagnosis of first episode of NAION in the study eye with symptom onset within 14 days prior to planned study drug administration/sham procedure
- Best corrected visual acuity score in the study eye is better than or equal to 20/250
- Clear ocular media and able to undergo adequate pupil dilation to allow a good fundus examination
- Present use or history of any treatment for the current episode of NAION, including systemic steroids, brimonidine, or traditional Chinese herbal medicine
- Prior episode of NAION in the study eye only
- Present use of drugs known to cause optic nerve or retinal toxicity at Day 1/Randomization, such as: chloroquine or hydroxychloroquine, ethambutol, Vigabatrin.
Enrollment in the Study
Annie Liu, CRC: 212-979-4729